Gregor Diagnostics, a molecular diagnostics company developing an at-home screening test for prostate cancer, closed a $900,000 round of seed financing, the company announced recently.

According to a release, the round was led by First Round and Green Park & Golf Ventures with participation from the Wisconsin Alumni Research Foundation, Nat Turner and Zach Weinberg of Flatiron Health as well as a follow-on investment from Health Wildcatters.

“We’re really trying to tackle this problem (prostate cancer) from both angles by decreasing overdiagnosis and overtreatment while enabling more effective detection of aggressive prostate cancer, and this is an important first step toward that goal,” Gregor Diagnostics CEO Tobias Zutz said in a statement.

The money will be used to allow the company to demonstrate the efficacy of the test in a set of patient samples. From the test, Gregor will be able to accurately send men to receive life-saving treatment.